Pembrolizumabe versus placebo após cirurgia e radiação em participantes com carcinoma cutâneo de células escamosas localmente avançado
This is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone